个体化快速补钾策略救治致命性重度低钾血症的实验研究
在20只健康成年日本大耳白兔上以氯化钡半数致死量溶液复制急性致命性重度低钾血症模型,随机分为常规补钾组和个体化快速补钾组各10只,均经耳缘静脉以微量注射泵输注3%氯化钾、目标血浆钾浓度4 mmol/L。常规组以0.4 mmol×kg⁻¹×h⁻¹标准速率持续输注;个体化快速组先5分钟内快速推注负荷剂量、重复至血浆钾升至3.5 mmol/L,再以0.4 mmol×kg⁻¹×h⁻¹维持。结果显示个体化快速组血浆钾升高幅度、尿钾浓度及细胞外液钾含量增加均显著高于常规组,补钾时间和心律失常持续时间缩短,总尿量、肾排钾量及跨细胞钾转移量显著减少,两组均未发生高钾血症,个体化快速组全部存活而常规组死亡4只。
要点
- 个体化快速补钾组血浆钾升高幅度2.40±0.33 mmol/L vs 常规组1.51±0.75 mmol/L,补钾时间2.1±0.7小时 vs 4.7±1.4小时。
- 个体化快速补钾组心律失常持续时间19.60±8.92分钟 vs 常规组71.80±9.84分钟,差异有统计学意义。
- 个体化快速补钾组10只全部存活,常规补钾组死亡4只,两组差异有统计学意义(P<0.01)。
- 两组均未发生高钾血症;个体化快速组总尿量6.40±1.78 mL vs 常规组13.60±4.69 mL,肾排钾量1.04±0.26 mmol vs 1.46±0.51 mmol。
- 两组补钾总量无显著差异,提示获益来自给药方式而非补钾总量。
适用人群与场景
- 健康成年日本大耳白兔,以氯化钡半数致死量溶液168 mg×5 mL⁻¹×kg⁻¹复制急性致命性重度低钾血症模型。
- 模型成功标准:给药后0.5小时血浆钾显著低于基线,2.0小时降至2.5 mmol/L以下并出现室性心律失常。
诊断标准与关键阈值
- 目标血浆钾浓度4 mmol/L;个体化快速补钾第一步负荷推注重复至血浆钾升至3.5 mmol/L后转为维持输注。
处置流程与药物剂量
- 两组均经耳缘静脉以微量注射泵输注3%氯化钾。
- 常规补钾组以0.4 mmol×kg⁻¹×h⁻¹标准速率持续输注。
- 个体化快速补钾组第一步5分钟内快速推注负荷剂量、重复至血浆钾升至3.5 mmol/L,第二步以0.4 mmol×kg⁻¹×h⁻¹速率维持输注。
红旗征与不能漏的情况
- 血浆钾降至2.5 mmol/L以下时出现室性心律失常,提示致命性重度低钾血症模型复制成功。
研究设计与关键结果
- 动物实验,20只健康成年日本大耳白兔随机分为常规补钾组和个体化快速补钾组各10只。
- 主要结果:个体化快速组血浆钾升高幅度2.40±0.33 mmol/L vs 常规组1.51±0.75 mmol/L,尿钾浓度164.94±18.07 mmol/L vs 108.35±19.67 mmol/L,细胞外液钾含量增加1.17±0.16 mmol vs 0.73±0.35 mmol,差异均有统计学意义(均P<0.05)。
- 个体化快速组补钾时间2.1±0.7小时 vs 常规组4.7±1.4小时,心律失常持续时间19.60±8.92分钟 vs 71.80±9.84分钟,差异有统计学意义。
- 个体化快速组总尿量6.40±1.78 mL vs 常规组13.60±4.69 mL,肾排钾量1.04±0.26 mmol vs 1.46±0.51 mmol,跨细胞钾转移量1.39±0.21 mmol vs 1.84±0.62 mmol,均显著减少(均P<0.05)。
- 两组补钾总量无显著差异;两组均未发生高钾血症;个体化快速组10只全部存活,常规组死亡4只,差异有统计学意义(P<0.01)。
证据类型、等级与局限
- 证据类型:动物实验(兔急性致命性重度低钾血症模型)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为个体化快速补钾策略可缩短纠正低钾血症的时间,是逆转重度低钾血症所致危及生命心律失常的更好选择,救援成功率高,补钾过程安全有效。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To explore the effectiveness and safety of the individual-specific rapid potassium supplementation strategy, and to provide experimental basis for treating fatal severe hypokalemia.
METHODS: An acute fatal severe hypokalemia model was reproduced in 20 healthy adult Japanese big ear white rabbits with half lethal dose (LD50) of barium chloride (BaCl2) solution 168 mg×5 mL-1×kg-1. The rabbits were divided into conventional potassium supplementation group and individual-specific rapid potassium supplementation group according to random number table method with 10 rabbits in each group. All the animals were injected with 3% KCl through the auricular marginal veins by a micro-injection pump, and the target plasma potassium concentration was 4 mmol/L. The rabbits in conventional potassium supplementation group were administered continuously potassium infusion at the standard infusion rate of 0.4 mmol×kg-1×h-1. And those in the individual-specific rapid potassium supplementation group were treated in two steps: first, a loading dose of potassium was rapidly injected within 5 minutes, and this step was repeated until the plasma potassium concentration increased to 3.5 mmol/L; second, a sustaining dose of potassium infusion was continued at the rate of 0.4 mmol×kg-1×h-1 after the increase in plasma potassium concentration. The changes in electrocardiogram, blood pressure, respiratory rate (RR), plasma potassium concentration, urine potassium concentration, urine volume, potassium content in extracellular fluid (ECF) and other parameters were monitored. The potassium supplementation, potassium excretion and potassium cross cell status were recorded. Adverse reactions and 7-day death were observed.
RESULTS: Since the BaCl2 administration, the plasma potassium concentration of all experimental rabbits were significantly lower than baseline at 0.5 hour, which was decreased below 2.5 mmol/L at 2.0 hours when the ventricular arrhythmias appeared, indicating the reproduction of fatal severe hypokalemia model was successful. There was no significant difference in gender, weight, baseline heart rate (HR), RR, mean arterial pressure (MAP), blood gas analysis or K+, Na+, Cl- levels between the two groups. Compared with baseline levels, MAP was significantly decreased and RR was significantly increased before potassium supplementation in both groups, but the parameters were improved significantly and restored to the baseline after potassium supplementation. There was no significant difference in MAP or RR during potassium supplementation between the two groups. The amount of potassium supplementation in two groups showed no significant differences. However, compared with the conventional potassium supplementation group, in the individual-specific rapid potassium supplementation group, the increase in plasma potassium concentration, urine potassium concentration, and the increase in potassium content in ECF were significantly increased [the increase in plasma potassium concentration (mmol/L): 2.40±0.33 vs. 1.51±0.75, urine potassium concentration (mmol/L): 164.94±18.07 vs. 108.35±19.67, the increase in potassium content in ECF (mmol): 1.17±0.16 vs. 0.73±0.35], the duration of potassium infusion was shortened (hours: 2.1±0.7 vs. 4.7±1.4), the total urine volume, renal excretion of potassium, and the amount of transcellular potassium shift were significantly decreased [total urine volume (mL): 6.40±1.78 vs. 13.60±4.69, renal excretion of potassium (mmol): 1.04±0.26 vs. 1.46±0.51, amount of transcellular potassium shift (mmol): 1.39±0.21 vs. 1.84±0.62], the duration of arrhythmia was shortened (minutes: 19.60±8.92 vs. 71.80±9.84), with statistically significant differences (all P < 0.05). Hyperkalemia did not occur in both groups. The rabbits of the individual-specific rapid potassium supplementation group were all alive, while 4 died in the conventional potassium supplementation group, and statistically significant difference was found between the two groups (P < 0.01).
CONCLUSIONS: These data demonstrate that the individual-specific rapid potassium supplementation strategy can shorten the time for correcting hypokalemia, which is a better option to reverse life-threatening arrhythmia caused by severe hypokalemia, with a high rescue success rate. The process of potassium supplement is safe and effective.
参考来源
- Du Y, Mou Y, Liu J, et al. [Experimental research on individual-specific rapid potassium supplementation strategy for fatal severe hypokalemia]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2018. PMID: 29764543. doi:10.3760/cma.j.issn.2095-4352.2018.05.004
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。